Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IDIX

Idenix Pharmaceuticals (IDIX) Stock Price, News & Analysis

Idenix Pharmaceuticals logo

About Idenix Pharmaceuticals Stock (NASDAQ:IDIX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Receive IDIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idenix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDIX Stock News Headlines

HS China A Pharmaceuticals (HSCAPI)
Did you know you can now trade Bitcoin in your regular brokerage account?
We’re on the edge of what could be a massive parabolic move in Bitcoin that pushes the price past all-time highs… and over $100K. There was a little-known move by the NYSE in late 2021 that opened up a “loophole” for anyone with a regular brokerage account to take advantage of Bitcoin. Combined with a Trump presidency—who says he wants to be known as the first “Crypto President”—this creates an unprecedented opportunity.
Syndax Pharmaceuticals (SNDX) Receives a Buy from Barclays
See More Headlines

IDIX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Idenix Pharmaceuticals investors own include NVIDIA (NVDA), Aclaris Therapeutics (ACRS), Ariad Pharmaceuticals (ARIA), Arena Pharmaceuticals (ARNA), Bristol Myers Squibb (BMY), Costco Wholesale (COST) and Dendreon (DNDNQ).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IDIX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:IDIX) was last updated on 6/29/2025 by MarketBeat.com Staff
From Our Partners